English
Home > Products > CAS NO 54423-47-1

China CAS NO 54423-47-1 Factory

To be a result of ours specialty and service consciousness, our enterprise has won an excellent status between buyers all around the globe for CAS NO 54423-47-1,54423-47-1,Corey lactone intermediate,Corey lactone advance intermediate,(3aR,4S,5R,6aS)-hexahydro, If possible, be sure to send your needs with a detailed list including the style/item and quantity you require. We will then deliver our greatest price ranges to you.
CAS NO 54423-47-1, We adopted technique and quality system management, based on ""customer orientated, reputation first, mutual benefit, develop with joint efforts"", welcome friends to communicate and cooperate from all over the world.

Related Products

Hot Products

  • Fmoc-Lys(Pal-Glu-OtBu)-OH

    Fmoc-Lys(Pal-Glu-OtBu)-OH

    Product Name:Fmoc-Lys(Pal-Glu-OtBu)-OH
    Molecular Formula:C46H69N3O8
    Molecular Weight:792.06
    CAS Registry Number:1491158-62-3
  • Betrixaban

    Betrixaban

    Product Name:Betrixaban
    Molecular Formula:C23H22ClN5O3
    Molecular Weight;451.91
    CAS Registry Number;330942-05-7
  • Nadifloxacin

    Nadifloxacin

    Product Name:Nadifloxacin
    Molecular Formula:C19H21FN2O4
    Molecular Weight;360.38
    CAS Registry Number;124858-35-1
  • Dicyandiamide

    Dicyandiamide

    Product Name:Dicyandiamide
    Molecular Formula:C2H4N4
    Molecular Weight;84.08
    CAS Registry Number;461-58-5
  • Pirarubicin

    Pirarubicin

    Product Name:Pirarubicin
    Molecular Formula:C32H37NO12
    Molecular Weight;627.64
    CAS Registry Number;72496-41-4
  • N-[(S)-(+)-1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanine

    N-[(S)-(+)-1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanine

    Product Name:N-[(S)-(+)-1-(Ethoxycarbonyl)-3-phenylpropyl]-L-alanine
    Molecular Formula:C15H21NO4
    Molecular Weight:279.34
    CAS Registry Number:82717-96-2
  • Related Blog
  • Reviews

  • Everything You Need To Know About Active Pharmaceutical Ingredients (API In Pharma)

    Sandoo, as a professional API manufactruer in China, we produces a wide range of active pharmaceutical ingredients which can be used in the production of medicines in different applications.

  • What Is Misoprostol Used For?

    Misoprostol, a derivative of prostaglandin E1, can be used in the treatment of duodenal ulcer, the prevention of anti-inflammatory induced peptic ulcer and the prevention of early pregnancy.It has the function of inhibiting the secretion of gastric acid and preventing the formation of ulcer, thus protecting the gastric mucosa...

  • Prostate Cancer and Darolutamide

    Prostate cancer results from uncontrollable growth of cancer cells in the prostate gland. The prostate gland is located below the bladder and in front of the rectum, and is only found in males. Almost all prostate cancers (more than 95% of primary prostate cancers) develop from the gland cells and are known as adenocarcinomas (National Cancer Institute, 2017).

  • Development Trend of China's Pharmaceutical Intermediate Industry

    The rapid development of China's pharmaceutical intermediate industry is closely related to its national policies. Since 2016, China has issued clear documents to encourage small and medium-sized enterprises to develop new drugs, including chemical raw materials. At the same time, the structural upgrading of the pharmaceutical industry in developed countries has promoted the transfer of global related industrial chains and promoted China's chemical raw material drug supply chain. In addition, the increase in Chinese radiography technology has boosted product demand.

  • Outsourcing of API Manufacturing – Are Strict Regulation and Quality Checks Necessary?

    API is fundamental to the modern drug manufacturing process and cutting cost should not be the only criteria that can be applied to the production of an active pharmaceutical ingredient as it can adversely affect human health if the above-mentioned regulations and practices are not followed strictly.

  • FDA approves lorlatinib for second- or third-line treatment of ALK-positive metastatic NSCLC

    On November 2, 2018, the Food and Drug Administration granted accelerated approval to lorlatinib (LORBRENA, Pfizer, Inc.) for patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease.

Send Inquiry

Hit enter to search or ESC to close
X
We use cookies to offer you a better browsing experience, analyze site traffic and personalize content. By using this site, you agree to our use of cookies. Privacy Policy
Reject Accept